Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: Technical recommendations

Riccardo Lencioni, Camillo Aliberti, Thierry De Baere, Ricardo Garcia-Monaco, Govindarajan Narayanan, Elizabeth O'Grady, William S. Rilling, Duncan Walker, Robert C.G. Martin

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Transcatheter hepatic arterial administration of irinotecan-loaded drug-eluting beads (DEBIRI) is used to treat liver-only or liver-dominant metastatic disease from colorectal cancer (CRC). Eligibility for DEBIRI should be established in each individual patient by a multidisciplinary team based on comprehensive clinical, imaging, and laboratory assessment. Standardization of DEBIRI technique and protocols would be expected to lead to improved efficacy and safety. The present article provides a set of technical recommendations for the use of DEBIRI in the treatment of hepatic CRC metastases.

Original languageEnglish (US)
Pages (from-to)365-369
Number of pages5
JournalJournal of Vascular and Interventional Radiology
Volume25
Issue number3
DOIs
StatePublished - Mar 5 2014

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: Technical recommendations'. Together they form a unique fingerprint.

  • Cite this

    Lencioni, R., Aliberti, C., De Baere, T., Garcia-Monaco, R., Narayanan, G., O'Grady, E., Rilling, W. S., Walker, D., & Martin, R. C. G. (2014). Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: Technical recommendations. Journal of Vascular and Interventional Radiology, 25(3), 365-369. https://doi.org/10.1016/j.jvir.2013.11.027